SCOPE Summit 2025: Sebastien Coppe Discusses Advancing Innovation in Clinical Trials
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sebastien Coppe, CEO, One2Treat, talks challenges faced by startups in advancing clinical trial innovation.
ACT: You were a part of panel discussion on start-up companies. Can you briefly discuss what the panel entailed?
Coppe: A few innovative startup companies were selected to share their insights on advancing innovation in clinical development and ensuring that pharma sponsors and CROs can effectively leverage these solutions. Additionally, there is a growing need to adopt a more patient-centric approach in clinical trials.
ACT: Startups often face challenges in gaining traction. What has been the biggest hurdle for One2Treat in advancing clinical trial innovation, and how are you overcoming it?
Coppe: Over the past two years, the FDA and EMA have provided valuable guidance, particularly in patient-focused drug development and optimal project management. While this guidance is helping pharma companies make progress, there remains some uncertainty about how regulators can further support the adoption of concrete methodologies.
At times, sponsors may be hesitant to embrace innovative opportunities, which underscores the need for clearer frameworks and greater confidence in emerging solutions.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
